Cost-effectiveness analysis of pembrolizumab versus standard of care in recurrent or metastatic squamous cell carcinoma of the head and neck
Open Access
- 1 April 2022
- journal article
- other
- Published by Wolters Kluwer Health in European Journal of Oncology Pharmacy
- Vol. 5 (2) , e00034
Abstract
Increasing costs of cancer treatment and anticancer drugs can create a financial burden on society and the individual. Pembrolizumab is an anti-PD-1 inhibitor immunotherapy approved for use in recurrent or metastatic head and neck squamous cell carcinoma. Limited data exists on the cost-effectiveness of pembrolizumab in this setting. This study compares the costeffectiveness of pembrolizumab against traditional chemotherapy using data from KEYNOTE-040. Published data from KEYNOTE-040 were used to create a model estimating treatment costs and overall survival benefit of pembrolizumab and traditional chemotherapy. Costs of treatment of toxicity-related events were obtained from previous literature and were incorporated into the model. Derivation of survival benefit gained from treatment was measured in quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) of pembrolizumab compared to the investigator's choice (IC) was $801,864/QALY. The average drug cost of pembrolizumab would have to approximately decrease by 63% in order to reach the cost-effective threshold of $100,000/ QALY. Pembrolizumab would have to confer a survival benefit of 0.88 QALYs per patient over the IC to reach the cost-effective threshold. Pembrolizumab is not considered cost effective at a threshold of $100,000/QALY based on survival data reported in KEYNOTE-040. Improved long-term outcomes of patients on this relatively new immunotherapy have yet to be reported. Inclusion of these data in the future would likely improve the cost-effectiveness calculations of pembrolizumab and other immunotherapies.Keywords
This publication has 23 references indexed in Scilit:
- Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-AnalysisJournal of Clinical Oncology, 2014
- Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic reviewHuman Vaccines & Immunotherapeutics, 2014
- The Economic Burden of Head and Neck Cancer: A Systematic Literature ReviewPharmacoEconomics, 2014
- Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopeciaActa Oncologica, 2013
- The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's ExperienceThe Oncologist, 2013
- Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patientsJournal of Medical Economics, 2012
- Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinibBritish Journal of Cancer, 2009
- Risk, Outcomes, and Costs of Radiation-Induced Oral Mucositis Among Patients With Head-and-Neck MalignanciesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- The Economic Cost of Squamous Cell Cancer of the Head and NeckJAMA Otolaryngology–Head & Neck Surgery, 2004
- Clinical reviewSquamous cell carcinomas of the head and neckCommentary: Head and neck carcinomas in the developing world: Fig 2BMJ, 2002